News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
CR Group L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Sold 2,156,717 shares
@ $0.2007, valued at
$432.9k
Sold 1,343,011 shares
@ $0.2007, valued at
$269.5k
Sold 431,343 shares
@ $0.2007, valued at
$86.6k
Sold 1,461,849 shares
@ $0.2007, valued at
$293.4k
|
|
| 09/27/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Sold 99,979 shares
@ $0.25, valued at
$25k
Sold 62,258 shares
@ $0.25, valued at
$15.6k
Sold 19,996 shares
@ $0.25, valued at
$5k
Sold 67,767 shares
@ $0.25, valued at
$16.9k
|
|
| 09/26/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Sold 2,031,313 shares
@ $0.2588, valued at
$525.7k
Sold 1,264,920 shares
@ $0.2588, valued at
$327.4k
Sold 406,263 shares
@ $0.2588, valued at
$105.1k
Sold 1,376,848 shares
@ $0.2588, valued at
$356.3k
|
|
| 08/14/2023 |
SC 13G/A
| CR Group L.P. reports a 19.9% stake in Avinger, Inc. |
| 08/09/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on Avinger Inc|
Txns:
| Granted 166 convertible preferred
@ $0.715, valued at
$118.7
Granted 310 convertible preferred
@ $0.715, valued at
$221.4
Granted 658 convertible preferred
@ $0.715, valued at
$470.6
Granted 53 convertible preferred
@ $0.715, valued at
$38.2
Granted 733 convertible preferred
@ $0.715, valued at
$523.9 |
|
| 08/09/2023 |
3
| CR Group L.P. (10% Owner) has filed a Form 3 on Avinger Inc |
| 07/14/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/13/2023 |
SC 13G
| CR Group L.P. reports a 19.9% stake in T2 Biosystems, Inc. |
| 07/06/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Granted 19,334,277 shares
@ $0
Granted 12,039,660 shares
@ $0
Granted 3,866,855 shares
@ $0
Granted 13,105,006 shares
@ $0 |
|
| 07/06/2023 |
3
| CR Group L.P. (10% Owner) has filed a Form 3 on T2 Biosystems, Inc. |
| 01/06/2021 |
SC 13G/A
| CR Group L.P. reports a 0.3% stake in Assertio Holdings, Inc. |
| 12/30/2020 |
SC 13G/A
| CR Group L.P. reports a 5.6% stake in Assertio Holdings, Inc. |
| 12/29/2020 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on Assertio Holdings, Inc.|
Txns:
| Sold 6,784,334 shares
@ $0.3745, valued at
$2.5M
Sold 1,982,851 shares
@ $0.3682, valued at
$730.1k
|
|
| 12/22/2020 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on Assertio Holdings, Inc.|
Txns:
| Sold 500,000 shares
@ $0.3776, valued at
$188.8k
Sold 500,000 shares
@ $0.3602, valued at
$180.1k
Sold 1,500,000 shares
@ $0.339, valued at
$508.5k
|
|
| 07/06/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/09/2020 |
SC 13D/A
| Capital Royalty L.P. reports a 48.5% stake in TEARLAB CORPORATION |
| 05/28/2020 |
3
| CR Group L.P. (10% Owner) has filed a Form 3 on Assertio Holdings, Inc. |
| 05/28/2020 |
SC 13G
| Capital Royalty L.P. reports a 15.8% stake in Assertio Holdings, Inc. |
| 05/22/2020 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 4,586,874 shares
@ $0
Disposed/sold 2,436,459 warrants
@ $0.0001, valued at
$243.6 |
|
| 05/22/2020 |
SC 13D/A
| Capital Royalty L.P. reports a 0% stake in Zyla Life Sciences |
| 05/21/2020 |
SC 13D
| Capital Royalty L.P. reports a 48.5% stake in TEARLAB CORPORATION |
| 02/13/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/03/2019 |
4
| Capital Royalty L.P. (10% Owner) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed of 4,586,874 shares
@ $0
Acquired 4,586,874 shares
@ $0
Disposed of 2,436,459 warrants
@ $0.0001, valued at
$243.6
Acquired 2,436,459 warrants
@ $0.0001, valued at
$243.6 |
|
| 02/11/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/28/2018 |
SC 13G
| Capital Royalty L.P. reports a 5.6% stake in Strongbridge Biopharma plc |
| 11/20/2018 |
SC 13D/A
| Capital Royalty L.P. reports a 39.8% stake in § 240. Valeritas Holdings, Inc. |
| 11/20/2018 |
4
| Capital Royalty L.P. (10% Owner) has filed a Form 4 on Valeritas Holdings Inc.|
Txns:
| Bought 4,224,605 shares
@ $0
Bought 1,264,997 shares
@ $0
Bought 7,427,065 shares
@ $0
Bought 2,083,333 shares
@ $0
Bought 4,224,605 options to buy
@ $0.6, valued at
$2.5M
Bought 1,264,997 options to buy
@ $0.6, valued at
$759k
Bought 7,427,065 options to buy
@ $0.6, valued at
$4.5M
Bought 2,083,333 options to buy
@ $0.6, valued at
$1.2M
Bought 4,224,605 options to buy
@ $0.48, valued at
$2M
Bought 1,264,997 options to buy
@ $0.48, valued at
$607.2k
Bought 7,427,065 options to buy
@ $0.48, valued at
$3.6M
|
|
| 04/07/2017 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/30/2017 |
4
| Capital Royalty L.P. (10% Owner) has filed a Form 4 on Valeritas Holdings Inc.|
Txns:
| Bought 437,836 shares
@ $10, valued at
$4.4M
Bought 154,727 shares
@ $10, valued at
$1.5M
Bought 490,234 shares
@ $10, valued at
$4.9M
Bought 2,116,803 shares
@ $10, valued at
$21.2M
Bought 800,400 shares
@ $10, valued at
$8M
|
|
| 03/30/2017 |
3/A
| Capital Royalty L.P. (10% Owner) has filed a Form 3/A on Valeritas Holdings Inc. |
|
|